Analysts Offer Predictions for MDGL Q1 Earnings

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Research analysts at B. Riley issued their Q1 2025 EPS estimates for shares of Madrigal Pharmaceuticals in a research report issued on Monday, November 4th. B. Riley analyst M. Mamtani expects that the biopharmaceutical company will post earnings per share of ($3.34) for the quarter. B. Riley has a "Neutral" rating and a $236.00 price target on the stock. The consensus estimate for Madrigal Pharmaceuticals' current full-year earnings is ($25.19) per share. B. Riley also issued estimates for Madrigal Pharmaceuticals' Q3 2025 earnings at ($2.86) EPS and Q4 2025 earnings at ($2.46) EPS.

A number of other brokerages have also recently issued reports on MDGL. JMP Securities increased their target price on shares of Madrigal Pharmaceuticals from $381.00 to $385.00 and gave the company a "market outperform" rating in a report on Tuesday, July 16th. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of Madrigal Pharmaceuticals in a report on Friday, October 11th. Citigroup lowered their target price on Madrigal Pharmaceuticals from $382.00 to $371.00 and set a "buy" rating on the stock in a report on Thursday, August 8th. Oppenheimer cut their price target on Madrigal Pharmaceuticals from $375.00 to $350.00 and set an "outperform" rating for the company in a research note on Wednesday, October 23rd. Finally, StockNews.com raised shares of Madrigal Pharmaceuticals to a "sell" rating in a research note on Saturday, October 12th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $347.33.

Madrigal Pharmaceuticals Price Performance

Shares of Madrigal Pharmaceuticals stock traded up $0.61 during trading on Wednesday, reaching $338.22. The company's stock had a trading volume of 592,353 shares, compared to its average volume of 441,774. The business has a 50 day moving average price of $232.32 and a 200-day moving average price of $245.11. The company has a market capitalization of $7.38 billion, a P/E ratio of -13.49 and a beta of -0.46. The company has a quick ratio of 5.93, a current ratio of 5.98 and a debt-to-equity ratio of 0.15. Madrigal Pharmaceuticals has a 12-month low of $133.99 and a 12-month high of $345.04.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($4.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($6.94) by $2.02. The firm had revenue of $62.18 million for the quarter, compared to analysts' expectations of $34.60 million. During the same period in the prior year, the company earned ($5.34) earnings per share.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD increased its position in shares of Madrigal Pharmaceuticals by 106.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 803,213 shares of the biopharmaceutical company's stock worth $214,491,000 after acquiring an additional 414,484 shares in the last quarter. Fiera Capital Corp purchased a new position in Madrigal Pharmaceuticals in the second quarter valued at about $32,335,000. Avoro Capital Advisors LLC lifted its stake in shares of Madrigal Pharmaceuticals by 5.7% during the second quarter. Avoro Capital Advisors LLC now owns 2,055,555 shares of the biopharmaceutical company's stock worth $575,884,000 after purchasing an additional 111,111 shares in the last quarter. Artal Group S.A. acquired a new position in shares of Madrigal Pharmaceuticals during the first quarter worth about $29,510,000. Finally, Point72 Asset Management L.P. grew its stake in shares of Madrigal Pharmaceuticals by 172.6% in the second quarter. Point72 Asset Management L.P. now owns 40,958 shares of the biopharmaceutical company's stock valued at $11,475,000 after buying an additional 97,387 shares in the last quarter. 98.50% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Madrigal Pharmaceuticals

In other news, CEO William John Sibold sold 6,363 shares of the firm's stock in a transaction on Monday, September 9th. The stock was sold at an average price of $243.83, for a total transaction of $1,551,490.29. Following the sale, the chief executive officer now owns 55,887 shares in the company, valued at $13,626,927.21. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, CEO William John Sibold sold 6,363 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $243.83, for a total transaction of $1,551,490.29. Following the transaction, the chief executive officer now directly owns 55,887 shares in the company, valued at $13,626,927.21. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Richard S. Levy sold 5,000 shares of the business's stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $300.94, for a total transaction of $1,504,700.00. Following the completion of the sale, the director now owns 11,012 shares of the company's stock, valued at approximately $3,313,951.28. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 22.80% of the stock is currently owned by insiders.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.